Avalo Therapeutics appoints Ron Philip to Board of Directors

Avalo Therapeutics, Inc.

Ron Philip appointed to board effective June 23, 2026; will serve until 2027 annual meeting.
Appointed to Compensation Committee and Science, Development and Commercial Advisory Committee.
Received non-qualified stock option to purchase 40,200 shares, vesting over 3 years.
Mr. Philip most recently was CEO of Orbital Therapeutics until its acquisition by Bristol-Myers Squibb in Dec 2025.
Board determined Mr. Philip satisfies Nasdaq independence standards.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.